专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明专利

DE3854933T2 未知
公开(公告)号：DE3854933T2
公开(公告)日：1996-09-19
申请号：DE3854933
申请日：1988-05-06
申请人： ENZO BIOCHEM INC
发明人： YANG HUEY-LANG , DONEGAN JAMES J
IPC分类号： C12N15/09 , A61K31/7088 , A61K48/00 , A61P31/00 , C12N15/10 , C12N15/70 , C12Q1/68 , C12Q1/689 , C12P19/34

32. 发明专利

CA2801771C SULFATION OF WNT PATHWAY PROTEINS 未知
公开(公告)号：CA2801771C
公开(公告)日：2021-08-17
申请号：CA2801771
申请日：2011-06-06
申请人： ENZO BIOCHEM INC
发明人： RABBANI JOSHUA , DONEGAN JAMES J
IPC分类号： C07K16/18 , A61K39/395 , A61P19/00 , A61P19/10 , C07K14/47 , C07K14/51 , C07K16/22
摘要： Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated, and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that, is not present, in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation. Additionally, a modified Wnt pathway protein, lacking a sulfation site that, is present in the native Wnt pathway protein is provided. Also provided, is methods of treating a subject having a disease exacerbated by Wnt activation. Additionally, a method of treating a subject having a disease exacerbated by Wnt inhibition is provided.

33. 发明专利

CA3126121A1 COMPOSITIONS AND METHODS AFFECTING THE SIGNALING PATHWAYS OF LRP RECEPTORS 未知
公开(公告)号：CA3126121A1
公开(公告)日：2010-02-11
申请号：CA3126121
申请日：2009-08-07
申请人： ENZO BIOCHEM INC
发明人： BHATTACHARYYA RIDDHI , CHENG WEI , DONEGAN JAMES J , ENEA VINCENZO , JIN RICHARD , LI XIAOFENG , LIANG YUANXING , LIU DAKAI , RABBANI ELAZAR , ZHANG GUANGRONG , ZHANG YAZHOU
摘要： The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

34. 发明专利

AT133451T 未知
公开(公告)号：AT133451T
公开(公告)日：1996-02-15
申请号：AT88107311
申请日：1988-05-06
申请人： ENZO BIOCHEM INC
发明人： YANG HUEY-LANG , DONEGAN JAMES J
IPC分类号： C12N15/09 , A61K31/7088 , A61K48/00 , A61P31/00 , C12N15/10 , C12N15/70 , C12Q1/68 , C12Q1/689 , C12P19/34

35. 发明专利

AU2014257219A1 Tolerizing treatments for autoimmune disease 未知
公开(公告)号：AU2014257219A1
公开(公告)日：2015-09-24
申请号：AU2014257219
申请日：2014-04-22
申请人： WEI LAI , DONEGAN JAMES , RABBANI ELAZAR , NUSSENBLATT RICHARD , ENZO BIOCHEM INC , LIU BAOYING
发明人： NUSSENBLATT RICHARD , LIU BAOYING , WEI LAI , RABBANI ELAZAR , DONEGAN JAMES J
IPC分类号： A61K35/14 , G01N33/50
摘要： The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age-related macular degeneration and uveitis.

36. 发明专利

CA2801771A1 SULFATION OF WNT PATHWAY PROTEINS 未知
公开(公告)号：CA2801771A1
公开(公告)日：2011-12-15
申请号：CA2801771
申请日：2011-06-06
申请人： ENZO BIOCHEM INC
发明人： RABBANI JOSHUA , DONEGAN JAMES J
IPC分类号： C07K14/51 , C07K14/47 , C07K14/705 , C07K14/71 , C07K16/18 , C07K16/22 , C07K16/28
摘要： Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated, and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that, is not present, in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation. Additionally, a modified Wnt pathway protein, lacking a sulfation site that, is present in the native Wnt pathway protein is provided. Also provided, is methods of treating a subject having a disease exacerbated by Wnt activation. Additionally, a method of treating a subject having a disease exacerbated by Wnt inhibition is provided.

37. 发明专利

CA3012497A1 COMPOSITIONS AND METHODS AFFECTING THE SIGNALING PATHWAYS OF LRP RECEPTORS 未知
公开(公告)号：CA3012497A1
公开(公告)日：2010-02-11
申请号：CA3012497
申请日：2009-08-07
申请人： ENZO BIOCHEM INC
发明人： RABBANI ELAZAR , LI XIAOFENG , LIU DAKAI , ZHANG YAZHOU , JIN RICHARD , BHATTACHARYYA RIDDHI , CHENG WEI , ZHANG GUANGRONG , LIANG YUANXING , ENEA VINCENZO , DONEGAN JAMES J
IPC分类号： A61K31/538 , A61K31/136 , A61K31/185 , A61K31/192 , A61K31/235 , A61P3/10
摘要： The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式